Skip to main content
OpenTrials
Completed

NCT Number: NCT03477591

Evaluating the Impact of Evidence-based Information About PSA Testing on Prostate Cancer Screening Decisions

Patient decision aids are tools that help guide individuals through a healthcare-related decision making process. They help users combine evidence-based information and recommendations by a health care provider with their personal needs, values and preferences. Through this project, Dr. Dobbins and her research team will explore whether the use of patient decision aids with high-quality and user-friendly summaries of research evidence, or summaries of research evidence alone, help to improve the quality of decision making by men facing prostate cancer screening decisions.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prostate Cancer Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

50 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

McMaster University

Hamilton, Ontario, L8P0A1, Canada

About this study

Guidelines for prostate screening in Canada are based on low-moderate quality evidence of effectiveness and screening is associated with potential harms. Patient Decision Aids (PDAs) are tools that assist users to understand treatment options, risks and benefits to align decisions with values and preferences. The investigators would now like to know whether use of a PDA alongside evidence-based information provided through the McMaster Optimal Aging Portal, or simply access to evidence-based information alone, can help users to make informed decisions about prostate cancer screening in men.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • English speaking men, > 50 years old

Exclusion criteria

  • History of prostate cancer or PSA test in the last 12 months

Treatment and study plan

Evidence-based information

Other

Evidence-based information on PSA testing such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).

Patient Decision Aid

Other

Patient Decision Aid for prostate cancer screening decision

Sham information

Other

Educational information not specific to PSA testing or cancer screening

Primary outcomes

  1. Decisional conflict

    Time frame: Change from baseline to 6-mo

    Decisional Conflict Scale

Secondary outcomes

  1. Decision quality

    Time frame: Change from baseline to 6-mo

    Decision Quality Worksheet for PSA testing

  2. Preparation for decision making

    Time frame: Change from baseline to 6-mo

    Preparation for decision making scale

  3. Screening behaviour

    Time frame: Change from baseline to 6-mo

    Congruency between self-reported screening status and stated decision

Sponsors and collaborators

Lead sponsor

McMaster University

Other

Collaborators

  • Canadian Cancer Society (CCS)

Registry information

Official study title

McMaster Choices Study: Evaluating the Impact of Evidence-based Information About PSA Testing on Prostate Cancer Screening Decisions

Important dates

Study start
2018
Primary completion
2019
Study completion
2021
First posted
Mar 26, 2018
Registry last updated
Oct 19, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.